IRIDS Virtual Science Talks

25^th of March 2026

13:00 - 14:00 CET

Register now

Tuberculosis (TB) remains one of the world’s deadliest infectious threats, claiming over 1.2 million lives annually.¹ While the pace of innovation has been increasing, significant gaps in the care cascade persist. As we commemorate World TB Day 2026, we invite you to join us for a comprehensive one-hour webinar connecting high-level clinical research with patient advocacy.¹

The session will provide a review of recent clinical and research advancements by Professor Christoph Lange, Medical Director of the Research Center Borstel, Leibniz Lung Center in Borstel, Germany. He will provide an expert overview of the most significant global developments — spanning treatment, diagnostics, prevention, and vaccines — while elaborating on how the integration of these advances provides the “power” behind country-led elimination efforts. In the second part, Ms. Oxana Rucșineanu, Lead of the Moldova National Association of Tuberculosis Patients “SMIT”, will provide the patient and advocate viewpoint. She will highlight how community engagement and advocacy ensure that scientific innovations reach the populations they are intended to serve.

This approach offers a holistic view of the TB landscape, bridging scientific breakthroughs with the lived experiences of patients. The webinar will conclude with a dedicated 10-minute interactive Q&A session, offering a forum for audience questions and a panel discussion with both speakers.

Disclaimer: This is a medical-scientific educational webinar for healthcare professionals

3^rd of February 2026

Watch the recording

Introducing the stewardship continuum: Spotlight on Sepsis and AMR

Join us for the third webinar in our 3-part series, where we will explore the role of Therapeutic Drug Monitoring (TDM) in optimizing antimicrobial dosing. Achieving and maintaining the right antibiotic concentration is essential — standard dosing can lead to sub-therapeutic levels, risking treatment failure and development of resistance, while toxic levels may harm the patient.

In this webinar, Prof. Jan De Waele, intensive care physician and President of the European Society of Intensive Care Medicine (ESICM), will share latest clinical evidence and recommendations from scientific societies. He will discuss how Therapeutic Drug Monitoring enables personalized antibiotic therapy, strengthens antibiotic stewardship, and supports global efforts to combat antimicrobial resistance (AMR) in the critical care environment.

In addition, the session will also address current challenges, including the underutilization of TDM due to limited access to drug-specific testing and inadequate turnaround times (TAT). Finally, Prof. De Waele will provide a forward-looking perspective on how advances in laboratory automation could streamline clinical workflows and further improve patient outcomes.

The webinar will conclude with a dedicated 10-minute Q&A session, providing participants the opportunity to engage directly with Prof. De Waele and discuss practical aspects of implementing TDM in clinical care.

15^th of January 2026

Watch the recording

Introducing the stewardship continuum: spotlight on sepsis and AMR.
Join us for the second webinar of a 3-part series, where we will discuss:

• Key considerations when implementing a rapid molecular diagnostic test for positive blood cultures into the laboratory and the advantages associated with BCID testing
• The benefits of rapid molecular BCID panels in improving microbiology workflow efficiency and their correlation with the standard of care
• Clinical implementation dynamics and outcomes associated with rapid BCID testing, including time to reporting of the first result and time to appropriate therapy 

Dr. De Koster will focus on the performance of the BCID panels, particularly in terms of turnaround time and the agreement between the rapid molecular assay and standard-of-care culture methods.

Dr. Demuyser will discuss the applicability of rapid molecular BCID panels in routine clinical practice. His presentation will highlight the opportunities and challenges of integrating these novel diagnostic tools into everyday workflows in a clinical microbiology laboratory. He will share practical insights from real-world implementation, emphasizing how such tools can support timely and evidence-based clinical decision-making.

The webinar will conclude with a dedicated 10-minute Q&A session, offering an open forum for audience questions and a panel discussion with all speakers.

13^th of November 2025

Watch the recording

This one hour webinar will focus on raising awareness that vector borne diseases like dengue fever are not only a threat to poor tropical and subtropical regions, but a growing threat to the entire globe.

The first speaker, Prof. Dr. Velavan will provide background on the critical disease, explain its ongoing spread into new areas like Europe and which tools are currently available and appropriate to control and diagnose the infection.

Our second speaker Simon Jochum (Roche) will shed light on Roche Diagnostics' commitment by introducing the recently launched Elecsys Dengue antigen test, its performance and medical value to the audience.

The webinar will conclude with a dedicated 10-minute Q&A session, offering an open forum for audience questions. 

Join us for this informative webinar on the Dengue virus to gain a comprehensive understanding of the disease, its local and global burden to patients and clinicians, tools in place to help the spread, and its evolving impact on global health.

25^th of September 2025

Watch the recording

Introducing the stewardship continuum: spotlight on sepsis and AMR.
Join us in the first webinar of a 3-part series, where we will discuss the results of the ADAPT-Sepsis trial (published in JAMA) and the implementation of the PCT assay from a laboratory perspective.  Early recognition of sepsis and rapid antibiotic treatments are the most important factors for patient survival. A number of studies have shown high levels of both the biomarkers C-reactive protein (CRP) and procalcitonin (PCT) in the blood of patients with sepsis and that they can fall to low levels during a spell of antibiotics. The ADAPT-Sepsis study aimed to find out whether the duration of antibiotic treatment given to patients with sepsis can be safely reduced following the close daily monitoring of these biomarkers.


Prof. Paul Dark, who led the ADAPT-Sepsis trial, will provide insights on whether the duration of antibiotic treatment given to patients with sepsis can be safely reduced by monitoring CRP or PCT.

Jonathan Clayton will provide insights into his role in the ADAPT-Sepsis trial, as well as the different considerations in implementing the PCT assay in the laboratory.

The webinar will conclude with a dedicated 10-minute Q&A session, offering an open forum for audience questions and a panel discussion with all speakers.